Terns Pharmaceuticals, Inc. Operating Cash Flow

Operating Cash Flow of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending March 31, 2022 was $-13.3 Million (a -0.67% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow increased by 51.83%
  • Annual Operating Cash Flow for 2021 was $-44.5 Million (a 45.26% increase from previous year)
  • Annual Operating Cash Flow for 2020 was $-30.7 Million (a -53.71% decrease from previous year)
  • Annual Operating Cash Flow for 2019 was $-66.2 Million (a 266.58% increase from previous year)
  • Twelve month Operating Cash Flow ending March 31, 2022 was $-43.5 Million (a -2.28% decrease compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 18.37% year-over-year
Trailing Operating Cash Flow for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-43.5 Million $-44.5 Million $-38.5 Million $-36.8 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of Terns Pharmaceuticals, Inc.

Most recent Operating Cash Flowof TERN including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-13.3
2021 $-13.39 $-8.08 $-8.76 $-14.32 $-44.55
2020 $-7.39 $-6.31 $-8.82 $-7.29 $-30.67
2019 $-66.22 $-66.24
2018 $-18.07

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.